ETHRIL 250
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ETHRIL 250 (ETHRIL 250).
ETHRIL 250 (valproate semisodium) increases GABA levels in the brain by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase, enhancing neuronal inhibition.
| Metabolism | Primarily hepatic via glucuronidation (30-50%) and mitochondrial beta-oxidation (40-60%); minor CYP2C9 and CYP2A6 involvement. |
| Excretion | Primarily renal elimination (70-80% unchanged), with 10-15% biliary/fecal elimination as metabolites; total clearance approximates 150 mL/min. |
| Half-life | Terminal elimination half-life of 6-8 hours in adults; prolonged to 12-15 hours in renal impairment (CrCl <30 mL/min), necessitating dose adjustment. |
| Protein binding | 85-90% bound primarily to albumin; binding is concentration-independent. |
| Volume of Distribution | 0.8-1.0 L/kg, indicating extensive tissue distribution; increased in edema or hypoalbuminemia states. |
| Bioavailability | Oral: 85-92% (first-pass metabolism minimal). Rectal: 70-80%. Intravenous and intramuscular: 100%. |
| Onset of Action | Oral: 30-60 minutes; peak effect at 1-2 hours. Intravenous: 5-10 minutes. Intramuscular: 15-30 minutes. |
| Duration of Action | Analgesia/antipyretic effects persist 4-6 hours with oral dosing; extended to 6-8 hours in hepatic impairment due to reduced clearance. |
250 mg orally every 8 hours, or 500 mg intravenously every 12 hours.
| Dosage form | TABLET |
| Renal impairment | CrCl 30-50 mL/min: 250 mg every 12 hours. CrCl 15-29 mL/min: 250 mg every 24 hours. CrCl <15 mL/min: 250 mg every 48 hours or after dialysis. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: 250 mg every 12 hours. Child-Pugh C: 250 mg every 24 hours. |
| Pediatric use | Neonates: 7.5 mg/kg every 12 hours. Infants and children: 10 mg/kg every 8 hours, maximum 500 mg per dose. |
| Geriatric use | Initiate at 250 mg every 12 hours; titrate based on renal function and clinical response, with caution for increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ETHRIL 250 (ETHRIL 250).
| Breastfeeding | Small amounts of ethinyl estradiol and drospirenone are excreted in breast milk; M/P ratio not established. Can reduce milk production and composition. Use with caution in nursing mothers only if necessary and with monitoring of infant for jaundice, estrogenic effects. |
| Teratogenic Risk | ETHRIL 250 (ethinyl estradiol and drospirenone) is contraindicated during pregnancy. First trimester: increased risk of congenital malformations, particularly cardiovascular and limb defects, and neural tube defects. Second and third trimesters: associated with potential fetal harm including masculinization of female fetuses and estrogenic effects. Use only if clearly needed and benefit outweighs risk. |
■ FDA Black Box Warning
Fatal hepatotoxicity (especially in children under 2 years) and teratogenicity (neural tube defects).
| Serious Effects |
Hepatic disease or significant dysfunction, known hypersensitivity to valproate, urea cycle disorders (especially ornithine transcarbamylase deficiency).
| Precautions | Hepatic dysfunction, pancreatitis, hyperammonemic encephalopathy, thrombocytopenia, polycystic ovary syndrome, weight gain, suicidal thoughts. |
Loading safety data…
| Fetal Monitoring | Monitor liver function, blood pressure, and signs of thromboembolism. Assess fetal growth and development via ultrasound if exposure occurs. Monitor for adverse effects in neonate if used near term. |
| Fertility Effects | ETHRIL 250 suppresses ovulation and is used as contraception. Reversible: fertility returns after discontinuation. No permanent effects on female fertility; no known impact on male fertility. |